NEW YORK (GenomeWeb) – Cancer molecular diagnostics firm Paradigm and TME Research, a cancer physician network, announced today that they have signed a deal to launch a precision medicine breast cancer registry.

Under the arrangement, the so-called Paradigm Neoadjuvant Breast Registry will use Paradigm's PCDx next-generation sequencing-based test and other technologies to characterize the genomes and profile the tumors of invasive breast cancer patients with the goal of identifying the best pre-surgical treatment for each individual.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.